Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | CCKBR | P32239 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TGM1 | P22735 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2826715 | 0.98 | LMNA (0.54) | LMNASMN1; SMN2HTTHTR2CCCKBR | |
| SCHEMBL3982387 | 0.90 | CCKBR (0.50) | LMNASMN1; SMN2HTTHTR2CCCKBR | |
| SCHEMBL12723408 | 0.90 | CCKBR (0.50) | LMNASMN1; SMN2HTTHTR2CCCKBR | |
| SCHEMBL5338500 | 0.88 | ALDH1A1 (0.50) | LMNASMN1; SMN2HTTHTR2CCCKBR | |
| SCHEMBL12722664 | 0.88 | ALDH1A1 (0.50) | LMNASMN1; SMN2HTTHTR2CCCKBR | |
| SCHEMBL12722614 | 0.88 | ALDH1A1 (0.50) | LMNASMN1; SMN2HTTHTR2CCCKBR | |
| SCHEMBL8393648 | 0.88 | LMNA (0.58) | LMNASMN1; SMN2HTTALDH1A1MEN1 | |
| SCHEMBL3947594 | 0.87 | BRD4 (0.52) | LMNASMN1; SMN2HTTCCKBRALDH1A1 | |
| Hydrochloric Acid SCHEMBL6307871 | 0.87 | ALDH1A1 (0.49) | LMNASMN1; SMN2HTTHTR2CCCKBR | |
| Hydrochloric Acid SCHEMBL3947595 | 0.86 | BRD4 (0.51) | LMNASMN1; SMN2HTTCCKBRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505750-B2 | 5-aminocyclylmethyl-oxazolidin-2-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-29 | — | — | US | disclosed |
| EP-2245028-B1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| EP-2320895-A2 | CDK MODULATORS | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-01-06 | — | — | US | disclosed |
| EP-2245028-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-03 | — | — | EP | disclosed |
| EP-1781669-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-10-13 | — | — | EP | disclosed |
| US-7655648-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| US-7655648-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009077989-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20070244091-A1 | Antibacterial Agents | GLAXO GROUP LIMITED, A CORPORATION | 2007-10-18 | — | — | US | disclosed |
| US-20070244091-A1 | Antibacterial Agents | GLAXO GROUP LIMITED, A CORPORATION | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244091-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | LMNA 2018/4885SMN1; SMN2 2534/4885HTT 3393/4885 |
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | LMNA 2517/4885SMN1; SMN2 1814/4885HTT 3918/4885 |
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | CNKSR1, KCNH1, CBR3 | LMNA 1886/4885SMN1; SMN2 2326/4885HTT 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.